DE602004032556D1 - - Google Patents

Info

Publication number
DE602004032556D1
DE602004032556D1 DE602004032556T DE602004032556T DE602004032556D1 DE 602004032556 D1 DE602004032556 D1 DE 602004032556D1 DE 602004032556 T DE602004032556 T DE 602004032556T DE 602004032556 T DE602004032556 T DE 602004032556T DE 602004032556 D1 DE602004032556 D1 DE 602004032556D1
Authority
DE
Germany
Prior art keywords
brc
breast cancer
cells
methods
discriminates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004032556T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of DE602004032556D1 publication Critical patent/DE602004032556D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
DE602004032556T 2003-09-24 2004-09-24 Active DE602004032556D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50557103P 2003-09-24 2003-09-24
PCT/JP2004/014438 WO2005028676A2 (en) 2003-09-24 2004-09-24 Method of diagnosing breast cancer

Publications (1)

Publication Number Publication Date
DE602004032556D1 true DE602004032556D1 (de) 2011-06-16

Family

ID=34375580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004032556T Active DE602004032556D1 (de) 2003-09-24 2004-09-24

Country Status (9)

Country Link
US (3) US7531300B2 (de)
EP (2) EP1668354A2 (de)
JP (3) JP4579246B2 (de)
CN (2) CN1898563B (de)
AT (1) ATE508202T1 (de)
DE (1) DE602004032556D1 (de)
ES (1) ES2365732T3 (de)
TW (2) TW200512298A (de)
WO (2) WO2005029067A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699937A2 (de) * 2003-12-05 2006-09-13 Erasmus MC Vorhersage der reaktion und des ausgangs einer anti-östrogen-therapie von metastisiertem brustkrebs
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
WO2006093337A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
DE602005022361D1 (de) * 2005-03-11 2010-08-26 Oncotherapy Science Inc Verfahren zur schädigung von zellen mit effektorfunktionen von anti-gfra1-antikörpern
EP1915462A2 (de) * 2005-07-28 2008-04-30 Oncotherapy Science, Inc. Rasgef1a-gen in verbindung mit krebs
CN101278060B (zh) 2005-07-29 2011-09-07 肿瘤疗法科学股份有限公司 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
EP2177910A1 (de) * 2005-11-10 2010-04-21 Aurelium Biopharma Inc. Gewebediagnose für Brustkrebs
WO2007061770A2 (en) * 2005-11-17 2007-05-31 University Of Maryland Method and system for analysis of time-series molecular quantities
CA2641410A1 (en) * 2006-02-03 2007-08-09 Messengerscape Co., Ltd. Genes for prognosis of cancer
WO2007091328A1 (ja) 2006-02-10 2007-08-16 Oncotherapy Science, Inc. 肺癌の治療方法
US20080108065A1 (en) * 2006-04-28 2008-05-08 Indra Poola Systems and diagnostic methods for breast cancer using mmp-1 markers
WO2008018642A2 (en) 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
EP3135773A1 (de) * 2006-09-27 2017-03-01 Sividon Diagnostics GmbH Verfahren zur brustkrebsprognose
AU2007345912B2 (en) * 2007-02-01 2011-11-24 Oriental Yeast Co., Ltd. Method of detecting mammary cancer cells
EP2118663B1 (de) 2007-02-15 2014-04-02 Universita' Degli Studi di Torino Regulierung der expression des pi3kb-protein bei tumoren
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
BRPI0815577A2 (pt) 2007-08-20 2015-03-03 Oncotherapy Science Inc Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
US8598125B2 (en) 2007-08-20 2013-12-03 Onco Therapy Science, Inc. CDCA1 peptide and pharmaceutical agent comprising the same
EP2209495A4 (de) * 2007-10-04 2012-05-02 Agency Science Tech & Res Taz/wwtr1 zur diagnose und behandlung von krebs
US8088715B2 (en) * 2007-11-13 2012-01-03 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
WO2009089548A2 (en) * 2008-01-11 2009-07-16 H. Lee Moffitt Cancer & Research Institute, Inc. Malignancy-risk signature from histologically normal breast tissue
WO2009116860A1 (en) * 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20100055705A1 (en) * 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR101174369B1 (ko) 2009-05-01 2012-08-16 한국생명공학연구원 유방암 진단용 바이오마커 및 유방암 진단제
US20120195488A1 (en) * 2009-05-29 2012-08-02 University Of Utah Research Foundation Methods and Compositions Related to Cellular Assays
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
EP2558598A4 (de) * 2010-04-13 2013-12-04 Univ Columbia Biomarker auf basis eines mit einer mehrfachkarzinom-invasion assoziierten mechanismus
EP2426216A1 (de) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostische und/oder prädiktive Biomarker und biologische Anwendungen dafür
EP2626431B1 (de) 2010-10-06 2015-09-16 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Verfahren zur diagnose, prognose und behandlung von brustkrebsmetastasen
JP5866669B2 (ja) 2010-10-26 2016-02-17 国立大学法人山口大学 乳がん発症感受性の判定方法
WO2012066093A1 (en) * 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
AU2011351990A1 (en) * 2010-12-29 2013-07-18 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
EP2771464B1 (de) 2011-10-27 2018-03-21 Yeda Research and Development Co. Ltd. Verfahren zur behandlung von karzinomen
CA3122778A1 (en) 2011-10-28 2013-05-02 Oncotherapy Science, Inc. Topk peptides and vaccines including the same
RU2619739C2 (ru) * 2012-05-30 2017-05-17 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ диагностики и прогноза при гиперпролиферативных заболеваниях молочной железы
WO2014010229A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse
KR102279844B1 (ko) * 2012-12-26 2021-07-21 코닌클리케 필립스 엔.브이. 타깃 유전자 발현의 선형 조합(들)을 사용한 세포 시그널링 경로 활성의 평가
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
BR112016007864A2 (pt) * 2013-10-09 2017-12-05 Fundacio Inst De Recerca Biomedica Irb Barcelona método para a prognose e tratamento de metástase de câncer
US20150323547A1 (en) * 2014-03-14 2015-11-12 Brian J. Czerniecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
EP3178839B1 (de) 2014-08-04 2023-10-04 Oncotherapy Science, Inc. Cdca1-abgeleitetes peptid und impfstoff damit
US10380834B2 (en) 2015-07-22 2019-08-13 Mark A. Litman Replaceable flexible electronic table top with display function for gaming tables
US10311681B2 (en) 2015-08-19 2019-06-04 Mark A. Litman Electronic table game platform with secondary random event displays
MX2018004308A (es) 2015-10-08 2018-05-01 Oncotherapy Science Inc Peptido derivado de foxm1 y vacuna que lo incluye.
US11609427B2 (en) 2015-10-16 2023-03-21 Ostendo Technologies, Inc. Dual-mode augmented/virtual reality (AR/VR) near-eye wearable displays
US11106273B2 (en) * 2015-10-30 2021-08-31 Ostendo Technologies, Inc. System and methods for on-body gestural interfaces and projection displays
KR102541256B1 (ko) 2015-11-30 2023-06-12 (주)아모레퍼시픽 Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
KR102475128B1 (ko) 2015-11-30 2022-12-07 (주)아모레퍼시픽 Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
US10345594B2 (en) 2015-12-18 2019-07-09 Ostendo Technologies, Inc. Systems and methods for augmented near-eye wearable displays
US10578882B2 (en) 2015-12-28 2020-03-03 Ostendo Technologies, Inc. Non-telecentric emissive micro-pixel array light modulators and methods of fabrication thereof
US10353203B2 (en) 2016-04-05 2019-07-16 Ostendo Technologies, Inc. Augmented/virtual reality near-eye displays with edge imaging lens comprising a plurality of display devices
US10453431B2 (en) 2016-04-28 2019-10-22 Ostendo Technologies, Inc. Integrated near-far light field display systems
US10522106B2 (en) 2016-05-05 2019-12-31 Ostendo Technologies, Inc. Methods and apparatus for active transparency modulation
PL3458610T3 (pl) 2016-05-25 2021-11-22 Inbiomotion S.L. Leczenie raka piersi w oparciu o status c-MAF
ES2874230T3 (es) * 2016-06-03 2021-11-04 Univ Kyushu Nat Univ Corp Proteína de fusión para mejorar la expresión de proteínas a partir de ARNm diana
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
KR102091747B1 (ko) * 2017-11-15 2020-03-20 주식회사 프로탄바이오 유방암 진단용 바이오마커 및 이의 용도
JP2021504339A (ja) 2017-11-22 2021-02-15 インバイオモーション エセ．エレ． ｃ−ＭＡＦの状態に基づく乳がんの治療的処置
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
CN109234384A (zh) * 2018-10-31 2019-01-18 中国医学科学院阜外医院 Hmgcl作为诊断标志物和治疗靶点在致密化不全型心肌病的应用
CA3118585A1 (en) * 2018-11-04 2020-05-07 Pfs Genomics, Inc. Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109811059B (zh) * 2019-03-31 2021-10-19 青岛泱深生物医药有限公司 生物标志物uggt1在宫颈疾病中的应用
EP4185862A1 (de) * 2020-09-14 2023-05-31 Duke University Zusammensetzungen und verfahren zur diagnose und behandlung einer dystonie
CN113025720B (zh) * 2021-04-28 2022-12-27 深圳市人民医院 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用
CN113466447B (zh) * 2021-05-28 2024-03-08 天津市肿瘤医院（天津医科大学肿瘤医院） 诊断胰腺癌预后的肿瘤标志物bzw1及检测试剂盒
CN114931665A (zh) * 2021-12-14 2022-08-23 广州医科大学 六型胶原α2亚基在神经修复产品中的应用
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
CN114561470B (zh) * 2022-03-19 2024-03-01 新乡医学院 三阴性乳腺癌分子标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
EP0874902A2 (de) * 1996-01-11 1998-11-04 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und nachweis von brustkrebs
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
AR031250A1 (es) * 2000-07-11 2003-09-17 Corixa Corp Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
US20050064402A1 (en) * 2000-10-03 2005-03-24 Goldsworthy Susan Mcdonald Tumor marker and methods of use
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US20030104418A1 (en) * 2001-04-27 2003-06-05 Chao Zhang Diagnostic markers for breast cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
WO2008018642A2 (en) 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Also Published As

Publication number Publication date
US20070269432A1 (en) 2007-11-22
CN1898563B (zh) 2011-11-23
US20090286856A1 (en) 2009-11-19
EP1668156B9 (de) 2012-02-22
EP1668354A2 (de) 2006-06-14
JP4579246B2 (ja) 2010-11-10
WO2005028676A2 (en) 2005-03-31
WO2005029067A2 (en) 2005-03-31
US20120010090A1 (en) 2012-01-12
JP2007506426A (ja) 2007-03-22
US7531300B2 (en) 2009-05-12
ES2365732T3 (es) 2011-10-10
JP4620670B2 (ja) 2011-01-26
TW200521243A (en) 2005-07-01
EP1668156A2 (de) 2006-06-14
TW200512298A (en) 2005-04-01
JP2007506424A (ja) 2007-03-22
JP2008092949A (ja) 2008-04-24
WO2005029067A3 (en) 2005-08-18
US8044193B2 (en) 2011-10-25
EP1668156B1 (de) 2011-05-04
CN1890381A (zh) 2007-01-03
CN1890381B (zh) 2011-06-22
CN1898563A (zh) 2007-01-17
WO2005028676A3 (en) 2005-09-15
ATE508202T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
DE602004032556D1 (de)
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2004031412A3 (en) Method for diagnosing pancreatic cancer
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2004031410A3 (en) Method for diagnosing testicular seminomas
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
TW200833846A (en) Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
TW200628614A (en) Methods for determining a chemotherapeutic regimen comprising 5-fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
WO2008021483A3 (en) Prognostic and diagnostic method for disease therapy
SG163614A1 (en) Colon cancer related gene tom34
WO2004031414A3 (en) Method for diagnosing prostate cancer
EP1565582A4 (de) Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
TW200504223A (en) Methods of assessment of drug metabolizing enzymes
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression